DE19681286T1 - New crystal form of olanzapine - Google Patents

New crystal form of olanzapine

Info

Publication number: DE19681286T1
Authority: DE; Germany
Prior art keywords: olanzapine; crystal form; new crystal; new; crystal
Prior art date: 1995-03-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

DE19681286T

Other languages

German (de)

Inventor

Charles Arthur Bunnell

Barry Arnold Hendriksen

Samuel Dean Larsen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Lilly Industries Ltd

Eli Lilly and Co

Original Assignee

Lilly Industries Ltd

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-24

Filing date

1996-03-22

Publication date

1998-04-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE19681286(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-03-22 Application filed by Lilly Industries Ltd, Eli Lilly and Co filed Critical Lilly Industries Ltd

1998-04-02 Publication of DE19681286T1 publication Critical patent/DE19681286T1/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicinal Preparation (AREA)

DE19681286T 1995-03-24 1996-03-22 New crystal form of olanzapine Withdrawn DE19681286T1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40956695A	1995-03-24	1995-03-24
PCT/US1996/003917 WO1996030375A1 (en)	1995-03-24	1996-03-22	Process and crystal forms of 2-methyl-thieno-benzodiazepine

Publications (1)

Publication Number	Publication Date
DE19681286T1 true DE19681286T1 (en)	1998-04-02

Family

ID=23621056

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DE69636313T Expired - Lifetime DE69636313T2 (en)	1995-03-24	1996-03-22	Use of crystal forms of 2-methylthienobenzodiazepines
DE69630324T Expired - Lifetime DE69630324T2 (en)	1995-03-24	1996-03-22	Process and crystal forms of 2-methylthienobenzodiazepines
DE19681286T Withdrawn DE19681286T1 (en)	1995-03-24	1996-03-22	New crystal form of olanzapine
DE69614426T Expired - Lifetime DE69614426T2 (en)	1995-03-24	1996-03-22	Crystal forms of a thieno (2,3-B) (1,5) benzodiazepine derivative and process for their preparation

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DE69636313T Expired - Lifetime DE69636313T2 (en)	1995-03-24	1996-03-22	Use of crystal forms of 2-methylthienobenzodiazepines
DE69630324T Expired - Lifetime DE69630324T2 (en)	1995-03-24	1996-03-22	Process and crystal forms of 2-methylthienobenzodiazepines

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE69614426T Expired - Lifetime DE69614426T2 (en)	1995-03-24	1996-03-22	Crystal forms of a thieno (2,3-B) (1,5) benzodiazepine derivative and process for their preparation

Country Status (48)

Country	Link
US (1)	US5736541A (en)
EP (3)	EP0733635B1 (en)
JP (1)	JPH11502535A (en)
KR (1)	KR100399688B1 (en)
CN (1)	CN1065536C (en)
AP (1)	AP828A (en)
AR (2)	AR010448A1 (en)
AT (4)	AT406771B (en)
AU (1)	AU706471B2 (en)
BG (1)	BG62619B1 (en)
BR (1)	BR9607790A (en)
CA (1)	CA2214005C (en)
CH (1)	CH690579A5 (en)
CO (1)	CO4650278A1 (en)
CZ (1)	CZ292688B6 (en)
DE (4)	DE69636313T2 (en)
DK (4)	DK1445259T3 (en)
EA (1)	EA000149B1 (en)
EE (1)	EE03489B1 (en)
EG (1)	EG23659A (en)
ES (3)	ES2208220T3 (en)
FI (1)	FI973750L (en)
GB (1)	GB2313835B (en)
HU (1)	HU224989B1 (en)
IL (1)	IL117610A (en)
IS (1)	IS1896B (en)
LT (1)	LT4349B (en)
LU (1)	LU90096B1 (en)
LV (1)	LV12018B (en)
MY (1)	MY114701A (en)
NO (1)	NO314663B1 (en)
NZ (1)	NZ306110A (en)
OA (1)	OA10510A (en)
PA (1)	PA8353701A1 (en)
PE (1)	PE44897A1 (en)
PL (1)	PL183723B1 (en)
PT (3)	PT733635E (en)
RO (1)	RO118872B1 (en)
SE (1)	SE9703205D0 (en)
SI (4)	SI9620040B (en)
SK (1)	SK284143B6 (en)
SV (1)	SV1996000031A (en)
TR (1)	TR199701017T1 (en)
TW (2)	TW442488B (en)
UA (1)	UA44765C2 (en)
WO (1)	WO1996030375A1 (en)
YU (1)	YU49478B (en)
ZA (2)	ZA962342B (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EG23659A (en) *	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine
CA2232559A1 (en) *	1995-09-29	1997-04-03	Charles Merritt Beasley Jr.	Method for treating a tic disorder
JP2000506528A (en) *	1996-03-11	2000-05-30	イーライ・リリー・アンド・カンパニー	How to treat insomnia
UA57727C2 (en) *	1996-03-11	2003-07-15	Елі Ліллі Енд Компані	Method for treating excessive aggression
CZ298198A3 (en) *	1996-03-25	1999-06-16	Eli Lilly And Company	Pharmaceutical preparation
EP0932407A4 (en) *	1996-03-25	2002-04-24	Lilly Co Eli	Method for treating migraine pain
WO1997035585A1 (en) *	1996-03-25	1997-10-02	Eli Lilly And Company	Anesthetic method
CN1494907A (en) *	1996-03-25	2004-05-12		Drug composition for curing pain
HU226167B1 (en) *	1996-09-23	2008-05-28	Lilly Co Eli	Olanzapine dihydrate d, its manufacturing and pharmaceutical compositions containing the same
ZA978515B (en) *	1996-09-23	1999-03-23	Lilly Co Eli	Intermediates and process for preparing olanzapine
AU6955998A (en) *	1997-04-15	1998-11-11	Eli Lilly And Company	Method for providing neuro-protective effects
US20030022889A1 (en) *	1997-04-15	2003-01-30	Bymaster Franklin P.	Method for providing neuro-protective effects
ZA982917B (en) *	1997-04-15	1999-10-06	Lilly Co Eli	Method for treating cerebral focal stroke.
EP1155696B1 (en) *	1997-04-15	2004-03-03	Eli Lilly And Company	Use of olanzapine for the manufacture of a medicament for neuroprotection
USRE43932E1 (en)	1997-07-18	2013-01-15	Novartis Ag	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en)	1997-09-30	2003-09-09	Eli Lilly And Company	2-methyl-thieno-benzodiazepine formulation
HU227400B1 (en) *	1998-09-30	2011-05-30	Lilly Co Eli	2-methyl-thieno-benzodiazepine formulation and its use
FR2802101B1 (en)	1999-12-10	2003-02-28	Aventis Pharma Sa	COMBINATION OF CYMEMAZINE AND AN ATYPICAL NEUROLEPTIC
US7022698B2 (en)	1999-12-28	2006-04-04	U & I Pharmaceuticals, Ltd.	Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en)	1999-12-28	2002-02-19	U & I Pharmaceuticals Ltd.	Polymorphic forms of olanzapine
DK1246827T3 (en) *	1999-12-28	2005-05-23	Cipla Ltd	New polymorphic forms of olanzapine
BR0114031A (en) *	2000-08-31	2003-09-09	Reddy S Lab Ltd	Process for the preparation of olanzapine hydrates and their conversion to crystalline forms of olanzapine
WO2002019998A2 (en) *	2000-09-08	2002-03-14	Eli Lilly And Company	A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) *	2001-01-04	2004-05-25	Geneva Pharmaceuticals, Inc.	Olanzapine crystal modification
AU2002340328A1 (en) *	2001-10-29	2003-05-12	Janet I. Cord	Olanzapine dihydrate-ii a process for its preparation and use thereof
CA2471341C (en)	2001-12-24	2012-01-24	Sun Pharmaceutical Industries Limited	Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
US7790905B2 (en) *	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
WO2003074474A2 (en) *	2002-03-01	2003-09-12	University Of South Florida	Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20100311701A1 (en) *	2002-02-15	2010-12-09	Transform Pharmaceuticals, Inc	Pharmaceutical Co-Crystal Compositions
WO2004089313A2 (en) *	2003-04-01	2004-10-21	Transform Pharmaceuticals, Inc.	Novel olanzapine forms and related methods of treatment
WO2004000284A1 (en) *	2002-06-21	2003-12-31	Transform Pharmaceuticals, Inc.	Pharmaceutical compositions with improved dissolution
US7927613B2 (en) *	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
EP2316468A1 (en)	2002-02-22	2011-05-04	Shire LLC	Delivery system and methods for protecting and administering dextroamphetamine
PL196814B1 (en)	2002-05-17	2008-02-29	Inst Farmaceutyczny	Method of obtaining polymorphous form of i olansapine
DE60336226D1 (en) *	2002-05-31	2011-04-14	Sandoz Ag	METHOD FOR PRODUCING OLANZAPINE FORM I
SI21270A (en) *	2002-07-15	2004-02-29	Krka, Tovarna Zdravil, D.D., Novo Mesto	Crystal forms of olanzapine and procedures for their preparation
PL202856B1 (en) *	2002-12-20	2009-07-31	Adamed Spo & Lstrok Ka Z Ogran	Method of obtaining pharmaceutically pure polymorphic form of I olanzapine
EP1575962A1 (en)	2002-12-24	2005-09-21	Teva Pharmaceutical Industries Limited	Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en)	2002-12-30	2012-05-22	Mcneil-Ppc, Inc.	Pharmaceutically acceptable propylene glycol solvate of naproxen
DE602004004453T2 (en) *	2003-03-12	2007-11-08	Teva Pharmaceutical Industries Ltd.	STABLE PHARMACEUTICAL COMPOSITIONS WITH DESLORATADIN
US20060135547A1 (en) *	2003-03-12	2006-06-22	Toth Zoltan G	Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) *	2003-06-18	2003-07-23	Generics Uk Ltd	Novel amorphous forms
GB0326148D0 (en)	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
AU2004291043A1 (en) *	2003-11-18	2005-06-02	3M Innovative Properties Company	Olanzapine containing transdermal drug delivery compositions
PL1611139T3 (en) *	2003-12-22	2008-10-31	Teva Pharma	Methods of preparing olanzapine
WO2005070938A1 (en)	2004-01-27	2005-08-04	Synthon B.V.	Stable salts of olanzapine
US20050272720A1 (en) *	2004-01-27	2005-12-08	Rolf Keltjens	Process for making olanzapine Form I
ES2253091B1 (en)	2004-07-27	2007-02-01	Inke, S.A.	MIXED SOLVATO OF OLANZAPINE, PROCEDURE FOR OBTAINING AND PROCEDURE OF OBTAINING THE FORM I OF OLANZAPINE FROM THE SAME.
ES2303462B1 (en) *	2004-09-06	2009-06-05	Shasun Chemicals And Drugs Limited	NEW PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICALLY PURE OLANZAPINE POLYMORPHIC FORM I.
EA200701065A1 (en) *	2004-11-16	2007-12-28	Элан Фарма Интернэшнл Лтд.	INJECTABLE COMPOSITIONS CONTAINING NANODISPERS Olanzapine
EP1838716B1 (en)	2005-01-05	2011-06-01	Eli Lilly And Company	Olanzapine pamoate dihydrate
CZ297214B6 (en) *	2005-02-02	2006-10-11	Zentiva, A. S.	Pharmaceutical composition containing olanzapine as active component and process for its preparation
US20100174066A1 (en) *	2005-03-21	2010-07-08	Venkataraman Sundaram	Process for preparing crystalline form i of olanzapine
US20070021605A1 (en) *	2005-07-20	2007-01-25	Rolf Keltjens	Process and composition for making olanzapine form i
EP1919923A1 (en) *	2005-08-17	2008-05-14	Synthon B.V.	A process for making olanzapine form i
GB0522474D0 (en) *	2005-11-03	2005-12-14	Actavis Group	A pharmaceutical formulation
HUP0501046A2 (en) *	2005-11-11	2007-08-28	Egis Gyogyszergyar Nyilvanosan	Process for the preparation of olanzapine
US8721202B2 (en)	2005-12-08	2014-05-13	Ncr Corporation	Two-sided thermal print switch
US8367580B2 (en)	2006-03-07	2013-02-05	Ncr Corporation	Dual-sided thermal security features
US8222184B2 (en)	2006-03-07	2012-07-17	Ncr Corporation	UV and thermal guard
ES2279715B1 (en)	2005-12-26	2008-06-01	Laboratorios Lesvi, S.L.	ORAL FORMULATION OF OLANZAPINE.
US7834176B2 (en)	2006-01-26	2010-11-16	Sandoz Ag	Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) *	2006-05-18	2007-12-20	Osinga Niels J	Olanzapine pharmaceutical composition
AR063043A1 (en) *	2006-09-29	2008-12-23	Synthon Bv	PHARMACEUTICAL COMPOSITION OF OLANZAPINA
US8039461B1 (en)	2006-11-10	2011-10-18	Pisgah Laboratories, Inc.	Physical states of a pharmaceutical drug substance
US7718649B1 (en)	2006-11-10	2010-05-18	Pisgah Labs, Inc.	Physical states of a pharmaceutical drug substance
PL381564A1 (en)	2007-01-22	2008-08-04	Koźluk Tomasz Nobilus Ent	The manner of production of basically clean variety of polymorphic olanzapine
CA2591644A1 (en) *	2007-06-14	2008-12-14	Apotex Pharmachem Inc.	Novel processes to form-i of olanzapine
US9056488B2 (en)	2007-07-12	2015-06-16	Ncr Corporation	Two-side thermal printer
US8883863B1 (en)	2008-04-03	2014-11-11	Pisgah Laboratories, Inc.	Safety of psuedoephedrine drug products
CN101735239B (en) *	2008-11-06	2011-08-31	齐鲁制药有限公司	Preparation method of anhydrous olanzapine crystal form II
EP2292624A1 (en)	2009-07-20	2011-03-09	LEK Pharmaceuticals d.d.	Process for the purification of olanzapine
AU2011293502B2 (en)	2010-08-23	2015-03-19	Alkermes Pharma Ireland Limited	Methods for treating antipsychotic-induced weight gain
CN102093386B (en) *	2011-01-05	2016-06-01	浙江华海药业股份有限公司	A kind of method preparing Zyprexa crystal form II
WO2012153347A2 (en)	2011-05-04	2012-11-15	Zentiva K.S.	Oral pharmaceutical composition of olanzapine form 1
CN107253993B (en)	2012-08-21	2021-10-22	詹森药业有限公司	Antibodies to olanzapine and uses thereof
EP2888284B1 (en)	2012-08-21	2022-07-06	Janssen Pharmaceutica NV	Antibodies to risperidone haptens and use thereof
TR201910347T4 (en) *	2012-08-21	2019-07-22	Janssen Pharmaceutica Nv	Antibodies to olanzapine haptens and their use.
EP2919788A4 (en)	2012-11-14	2016-05-25	Univ Johns Hopkins	METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
CN103848847B (en) *	2012-12-04	2018-02-06	广东东阳光药业有限公司	A kind of method that improvement prepares Olanzapine and its crystal formation II
JP6008734B2 (en) *	2012-12-20	2016-10-19	株式会社トクヤマ	Olanzapine type II crystal production method
CN103145731B (en) *	2013-02-26	2014-02-19	江苏豪森药业股份有限公司	Olanzapine crystal form and its preparation method and use
KR20240130825A (en)	2022-01-20	2024-08-29	테바 파마슈티컬스 인터내셔널 게엠베하	Olanzapine, compositions thereof and methods of use thereof
AU2024208071A1 (en)	2023-01-10	2025-06-12	Medincell Sa	Olanzapine compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4115568A (en) *	1974-11-26	1978-09-19	Lilly Industries Limited	Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en)	1976-10-06	1979-07-04	Wyeth John & Brother Ltd	Pharmaceutial dosage forms
CA1097233A (en)	1977-07-20	1981-03-10	George K. E. Gregory	Packages
US4237279A (en) *	1979-07-27	1980-12-02	Eli Lilly And Company	Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en)	1981-12-02	1989-01-18	Wyeth John & Brother Ltd	Solid shaped articles
US5039540A (en)	1989-08-14	1991-08-13	Neophore Technologies, Inc.	Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en)	1989-08-14	1992-01-07	Neophore Technologies, Inc.	Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) *	1990-04-25	1990-06-20	Lilly Industries Ltd	Pharmaceutical compounds
US5229382A (en) *	1990-04-25	1993-07-20	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
EP0582368B1 (en) *	1992-05-29	2001-01-24	Eli Lilly And Company Limited	Thienobenzodiazepine derivatives for treatment of CNS disorders
US5439888A (en) *	1994-03-04	1995-08-08	Eli Lilly And Company	Antithrombotic agents
US5457101A (en) *	1994-06-03	1995-10-10	Eli Lilly And Company	Thieno[1,5]benzoidiazepine use
EG23659A (en) *	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine

1996
- 1996-03-21 EG EG19960250A patent/EG23659A/en active
- 1996-03-22 NZ NZ306110A patent/NZ306110A/en not_active IP Right Cessation
- 1996-03-22 TW TW085103500A patent/TW442488B/en not_active IP Right Cessation
- 1996-03-22 DE DE69636313T patent/DE69636313T2/en not_active Expired - Lifetime
- 1996-03-22 CN CN96192775A patent/CN1065536C/en not_active Expired - Lifetime
- 1996-03-22 ES ES00203573T patent/ES2208220T3/en not_active Expired - Lifetime
- 1996-03-22 PT PT96302000T patent/PT733635E/en unknown
- 1996-03-22 SI SI9620040A patent/SI9620040B/en not_active IP Right Cessation
- 1996-03-22 CO CO96014567A patent/CO4650278A1/en unknown
- 1996-03-22 AU AU54279/96A patent/AU706471B2/en not_active Ceased
- 1996-03-22 IL IL11761096A patent/IL117610A/en not_active IP Right Cessation
- 1996-03-22 SK SK1218-97A patent/SK284143B6/en not_active IP Right Cessation
- 1996-03-22 ZA ZA9602342A patent/ZA962342B/en unknown
- 1996-03-22 ES ES03077455T patent/ES2266719T3/en not_active Expired - Lifetime
- 1996-03-22 DE DE69630324T patent/DE69630324T2/en not_active Expired - Lifetime
- 1996-03-22 PT PT00203573T patent/PT1095941E/en unknown
- 1996-03-22 EP EP96302000A patent/EP0733635B1/en not_active Expired - Lifetime
- 1996-03-22 WO PCT/US1996/003917 patent/WO1996030375A1/en not_active Ceased
- 1996-03-22 LU LU90096A patent/LU90096B1/en active
- 1996-03-22 BR BR9607790A patent/BR9607790A/en not_active IP Right Cessation
- 1996-03-22 SI SI9630636T patent/SI1095941T1/en unknown
- 1996-03-22 EE EE9700232A patent/EE03489B1/en not_active IP Right Cessation
- 1996-03-22 CH CH02245/97A patent/CH690579A5/en not_active IP Right Cessation
- 1996-03-22 AP APAP/P/1997/001065A patent/AP828A/en active
- 1996-03-22 AR ARP960101875A patent/AR010448A1/en unknown
- 1996-03-22 EA EA199700262A patent/EA000149B1/en not_active IP Right Cessation
- 1996-03-22 HU HU9802824A patent/HU224989B1/en not_active IP Right Cessation
- 1996-03-22 DK DK03077455T patent/DK1445259T3/en active
- 1996-03-22 GB GB9719819A patent/GB2313835B/en not_active Expired - Fee Related
- 1996-03-22 PE PE1996000203A patent/PE44897A1/en not_active IP Right Cessation
- 1996-03-22 SI SI9630345T patent/SI0733635T1/en unknown
- 1996-03-22 PL PL96322501A patent/PL183723B1/en not_active IP Right Cessation
- 1996-03-22 DE DE19681286T patent/DE19681286T1/en not_active Withdrawn
- 1996-03-22 FI FI973750A patent/FI973750L/en unknown
- 1996-03-22 MY MYPI96001085A patent/MY114701A/en unknown
- 1996-03-22 EP EP00203573A patent/EP1095941B1/en not_active Expired - Lifetime
- 1996-03-22 KR KR1019970706591A patent/KR100399688B1/en not_active Ceased
- 1996-03-22 JP JP8529532A patent/JPH11502535A/en not_active Ceased
- 1996-03-22 DK DK96302000T patent/DK0733635T3/en active
- 1996-03-22 TW TW085103499A patent/TW513432B/en not_active IP Right Cessation
- 1996-03-22 DE DE69614426T patent/DE69614426T2/en not_active Expired - Lifetime
- 1996-03-22 AT AT0902196A patent/AT406771B/en not_active IP Right Cessation
- 1996-03-22 CA CA002214005A patent/CA2214005C/en not_active Expired - Fee Related
- 1996-03-22 DK DK00203573T patent/DK1095941T3/en active
- 1996-03-22 AT AT00203573T patent/ATE251627T1/en active
- 1996-03-22 ZA ZA9602344A patent/ZA962344B/en unknown
- 1996-03-22 UA UA97094737A patent/UA44765C2/en unknown
- 1996-03-22 RO RO97-01761A patent/RO118872B1/en unknown
- 1996-03-22 PT PT03077455T patent/PT1445259E/en unknown
- 1996-03-22 AT AT03077455T patent/ATE331719T1/en active
- 1996-03-22 SI SI9630743T patent/SI1445259T1/en unknown
- 1996-03-22 YU YU17796A patent/YU49478B/en unknown
- 1996-03-22 AR ARP960101876A patent/AR002719A1/en unknown
- 1996-03-22 AT AT96302000T patent/ATE204280T1/en active
- 1996-03-22 TR TR97/01017T patent/TR199701017T1/en unknown
- 1996-03-22 ES ES96302000T patent/ES2159346T3/en not_active Expired - Lifetime
- 1996-03-22 EP EP03077455A patent/EP1445259B1/en not_active Expired - Lifetime
- 1996-03-22 CZ CZ19973000A patent/CZ292688B6/en not_active IP Right Cessation
- 1996-05-09 SV SV1996000031A patent/SV1996000031A/en not_active Application Discontinuation
- 1996-07-25 US US08/686,989 patent/US5736541A/en not_active Expired - Lifetime
- 1996-10-18 PA PA19968353701A patent/PA8353701A1/en unknown
1997
- 1997-09-05 SE SE9703205A patent/SE9703205D0/en not_active Application Discontinuation
- 1997-09-08 LV LVP-97-163A patent/LV12018B/en unknown
- 1997-09-16 LT LT97-148A patent/LT4349B/en not_active IP Right Cessation
- 1997-09-22 NO NO19974365A patent/NO314663B1/en not_active IP Right Cessation
- 1997-09-22 BG BG101900A patent/BG62619B1/en unknown
- 1997-09-22 IS IS4564A patent/IS1896B/en unknown
- 1997-09-23 DK DK108997A patent/DK108997A/en not_active Application Discontinuation
- 1997-09-24 OA OA70082A patent/OA10510A/en unknown

Also Published As

Publication number	Publication date
IL117610A (en)	2001-08-26
EP0733635A1 (en)	1996-09-25
EP0733635B1 (en)	2001-08-16
AP828A (en)	2000-04-28
CZ300097A3 (en)	1997-12-17
PT733635E (en)	2001-12-28
CO4650278A1 (en)	1998-09-03
PT1095941E (en)	2004-02-27
DE69630324D1 (en)	2003-11-13
ZA962344B (en)	1997-09-22
HUP9802824A3 (en)	2000-01-28
SI9620040A (en)	1998-06-30
ES2159346T3 (en)	2001-10-01
ES2208220T3 (en)	2004-06-16
SK121897A3 (en)	1998-03-04
SE9703205L (en)	1997-09-05
EP1445259A1 (en)	2004-08-11
HUP9802824A2 (en)	1999-06-28
EP1095941B1 (en)	2003-10-08
ATA902196A (en)	2000-01-15
DK108997A (en)	1997-11-12
DE69630324T2 (en)	2004-07-29
GB9719819D0 (en)	1997-11-19
PE44897A1 (en)	1997-10-22
EP1095941A1 (en)	2001-05-02
AR002719A1 (en)	1998-04-29
PL183723B1 (en)	2002-07-31
CN1179160A (en)	1998-04-15
DE69614426D1 (en)	2001-09-20
HK1013988A1 (en)	1999-09-17
LV12018A (en)	1998-04-20
SK284143B6 (en)	2004-10-05
SI1445259T1 (en)	2006-10-31
SI1095941T1 (en)	2003-12-31
SV1996000031A (en)	1998-03-27
LT4349B (en)	1998-05-25
KR19980703188A (en)	1998-10-15
CN1065536C (en)	2001-05-09
SI0733635T1 (en)	2002-06-30
AU706471B2 (en)	1999-06-17
FI973750A0 (en)	1997-09-22
IS1896B (en)	2003-10-20
EG23659A (en)	2007-03-26
ATE331719T1 (en)	2006-07-15
IL117610A0 (en)	1996-07-23
CA2214005A1 (en)	1996-10-03
GB2313835B (en)	1998-09-16
ATE251627T1 (en)	2003-10-15
AU5427996A (en)	1996-10-16
CH690579A5 (en)	2000-10-31
LV12018B (en)	1998-09-20
LT97148A (en)	1998-01-26
DE69614426T2 (en)	2002-05-23
NZ306110A (en)	1998-09-24
AP9701065A0 (en)	1997-10-31
AR010448A1 (en)	2000-06-28
DK1095941T3 (en)	2004-02-16
DE69636313T2 (en)	2007-05-31
FI973750A7 (en)	1997-09-22
FI973750L (en)	1997-09-22
UA44765C2 (en)	2002-03-15
AT406771B (en)	2000-08-25
BG62619B1 (en)	2000-03-31
PL322501A1 (en)	1998-02-02
NO314663B1 (en)	2003-04-28
US5736541A (en)	1998-04-07
NO974365L (en)	1997-09-22
EE03489B1 (en)	2001-08-15
YU17796A (en)	1999-03-04
ES2266719T3 (en)	2007-03-01
IS4564A (en)	1997-09-22
LU90096B1 (en)	1997-07-22
TW513432B (en)	2002-12-11
PA8353701A1 (en)	1998-09-18
PT1445259E (en)	2006-10-31
OA10510A (en)	2002-04-24
EA000149B1 (en)	1998-10-29
EP1445259B1 (en)	2006-06-28
ZA962342B (en)	1997-09-22
BG101900A (en)	1999-03-31
MX9707183A (en)	1997-11-29
JPH11502535A (en)	1999-03-02
KR100399688B1 (en)	2004-02-18
DK0733635T3 (en)	2001-10-08
BR9607790A (en)	1998-07-07
MY114701A (en)	2002-12-31
EE9700232A (en)	1998-04-15
DE69636313D1 (en)	2006-08-10
TW442488B (en)	2001-06-23
CA2214005C (en)	2001-07-03
HU224989B1 (en)	2006-05-29
DK1445259T3 (en)	2006-10-16
EA199700262A1 (en)	1998-02-26
ATE204280T1 (en)	2001-09-15
YU49478B (en)	2006-05-25
CZ292688B6 (en)	2003-11-12
SI9620040B (en)	2002-02-28
SE9703205D0 (en)	1997-09-05
GB2313835A (en)	1997-12-10
NO974365D0 (en)	1997-09-22
WO1996030375A1 (en)	1996-10-03
TR199701017T1 (en)	1998-01-21
RO118872B1 (en)	2003-12-30

Publication	Publication Date	Title
DE19681286T1 (en)	1998-04-02	New crystal form of olanzapine
DE69634998D1 (en)	2005-09-01	Control of edges
DE69635700D1 (en)	2006-03-30	NEW ENDOGLUKANASE
DE69635284D1 (en)	2006-02-23	NEW SUBSTITUTED NAPTHOPYRANEES
DE69533361D1 (en)	2004-09-16	IMPLEMENTATION OF HYDROCARBONS
DE69622504D1 (en)	2002-08-29	liquid crystal projector
FI962932A0 (en)	1996-07-22	Modulators of anchor protein function
DE69628195D1 (en)	2003-06-18	USE OF XYLOGLUCANE DOTRANSGLYCOSYLASE
DE69622942D1 (en)	2002-09-19	Liquid-crystal ANZEIGVORRICHTUNG
DE59303962D1 (en)	1996-10-31	Layable bridge
DE59609659D1 (en)	2002-10-17	LIQUID CONSTRUCTION OF THICKENING AGENTS
DE59503068D1 (en)	1998-09-10	Transition bridge
DE69622801D1 (en)	2002-09-12	NEW CARBAPEN DERIVATIVES
DE59406920D1 (en)	1998-10-22	Layable bridge
DE69530580D1 (en)	2003-06-05	CONTINUOUS BLEACHING OF ALKYL POLYGLYCOSIDES
DE69627732D1 (en)	2003-06-05	Modified composition of asphalt cement
DE19681567T1 (en)	1998-10-15	Liquid crystal composition
DE69605708D1 (en)	2000-01-27	Purification of pentafluoroethane
DE69515021D1 (en)	2000-03-16	Alignment of interferometers
DE59607408D1 (en)	2001-09-06	Mixtures of monoazopyridone dyes
DE59302718D1 (en)	1996-07-04	Layable bridge
DE59303961D1 (en)	1996-10-31	Removable bridge
KR970013825U (en)	1997-04-28	Bridge reinforcement
DE59500958D1 (en)	1997-12-11	LINKED BRIDGE
DE59801681D1 (en)	2001-11-15	New crystal modification of thiazine indigo

Legal Events

Date	Code	Title	Description
2003-06-18	8141	Disposal/no request for examination